The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Drug delivery into the brain is regulated by the blood–brain interfaces. The blood–brain
barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid …

Parkinson's disease (PD) is associated with a loss of neurons from the midbrain. The cause
of PD is unknown, but it is established that certain neurotoxins can cause similar syndromes …

A major pathological hallmark of Alzheimer's disease is accumulation of amyloid-β in senile
plaques in the brain. Evidence is accumulating that decreased clearance of amyloid-β from …

Species differences occur in the brain concentrations of drugs, but the reasons for these
differences are not yet apparent. This study was designed to compare brain uptake of three …

The blood–brain barrier (BBB) is the interface between the central nervous system and
systemic circulation. It tightly regulates what enters and is removed from the brain …

Background Numerous knockout mouse studies have revealed that P‐glycoprotein (P‐gp)
significantly limits drug distribution across the mouse blood‐brain barrier (BBB). To …

There is considerable interest in the therapeutic and adverse outcomes of drug interactions
at the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). These …

Introduction P‐glycoprotein (P‐gp) is an efflux transporter responsible for the transport of
various drugs across the blood‐brain barrier (BBB). Loss of P‐gp function with age may be …

Background The blood brain barrier (BBB) controls the brain microenvironment and limits
penetration of the central nervous system (CNS) by chemicals, thus creating an obstacle to …